GENinCode (LON:GENI) Hits New 52-Week Low – What’s Next?

GENinCode Plc (LON:GENI)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 0.79 and last traded at GBX 0.79, with a volume of 17890465 shares changing hands. The stock had previously closed at GBX 0.88.

GENinCode Trading Up 1.3%

The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74. The firm has a fifty day simple moving average of GBX 1.02 and a two-hundred day simple moving average of GBX 1.26. The firm has a market cap of £6.10 million, a PE ratio of -0.39 and a beta of 0.59.

GENinCode (LON:GENI) last posted its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The business had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. Equities analysts forecast that GENinCode Plc will post -7.1299999 EPS for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.